By IANS
Mumbai : Gujarat based drug maker Sun Pharmaceutical Industries said Monday it had received a green signal from the US Food and Drug Administration (USFDA) to market the generic version of cancer drug Amifostine injections.
Announcing this to the Bombay Stock Exchange (BSE), the company said that Sun Pharma was the first to file an abbreviated new drug application (ANDA) at USFDA for the marketing of this generic injection, which has reported annual sales of approximate $80 million.
The drug is a generic version of MedImmune’s Ethyol and is covered under three patents.
The ANDA was filed for certifications against all the patents, as MedImmune has filed a suit in the District Court of Maryland. The case is under litigation.
According to company, Amifostine injection is administered to curb damage to kidneys of patients suffering from advanced stage of ovarian cancer.